Apple: Consensus Estimates For Q2 2021

Apple (NASDAQ: AAPL) will be reporting their fiscal second quarter on April 28th after market close. Analysts have a consensus $152 12-month price target on the company, via a total of 40 analysts, with 11 analysts having strong buy ratings. 21 analysts meanwhile have buy ratings, 6 have hold ratings, one analyst has a sell rating, and one has a strong sell on the company. The street high comes from Evercore ISI with a $175 price target, and the lowest target sits at $83.

27 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 27 analysts is $76.87 billion; this number has been revised upwards from $74 billion at the start of the year. The highest revenue estimate is $83.2 billion, while the lowest is $70.9 billion.

Onto EBITDA estimates, there are currently only 10 analysts who have second-quarter EBITDA estimates. The mean is currently $22.5 billion, with this number having been revised down from $20.2 billion at the start of the year. Street high is a $23.9 billion EBITDA estimate and the lowest is $20.3 billion.

Analysts estimate that quarterly earnings per share will come in at $0.98, with this number being slightly revised up from $0.90 at the start of the year. Street high is currently $1.09 and the lowest estimate is $0.85 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

8 Mining Stocks Our Viewers Asked Us to Review | Sept 14th-18th

Canada Is Finally Fast-Tracking New Mines | John Passalacqua – First Phosphate

Gold & Silver Just Added $2 Billion to This Project | Aya Gold – Bourmadine PEA

Recommended

Cambria Gold Drills 166 g/t Gold and 3,383 g/t Silver Over 3.1 Metres at Premier

Selkirk Copper’s Minto PEA Outlines $494 Million After-Tax NPV and 47.8% IRR

Related News

Medmen: Canaccord Reiterates $0 Price Target, Sell Rating

On December 7th, Medmen Enterprises’ (CSE: MMEN) reported first-quarter fiscal 2021 financial results. Medmen reported...

Wednesday, December 9, 2020, 10:50:51 AM

Tilray: Analysts Leave Targets Unchanged After MedMen Investment

On August 17, Tilray (NASDAQ: TLRY) made the announcement that they formed a new limited...

Thursday, August 19, 2021, 01:03:00 PM

Echelon Initiates Coverage On Freeman Gold With $1.10 Price Target

Yesterday, Echelon Partners initiated coverage on Freeman Gold Corp (CSE: FMAN) with a C$1.10 12-month...

Wednesday, December 2, 2020, 03:31:00 PM

Else Nutrition: Canaccord Cuts Target To $2.00 After Financing

On June 22, Else Nutrition (TSX: BABY) announced that it raised $7.29 million by selling...

Monday, July 4, 2022, 04:33:00 PM

Cameco: BMO Lifts Price Target To $42 Following Positive Uranium Price Move

On March 30th, BMO Capital Markets raised their rating and 12-month price target on Cameco...

Sunday, April 3, 2022, 11:08:00 AM